Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Allstate Corp (ALL) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Allstate CorpTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Allstate Corp vs Inovio Pharmaceuticals Inc — how do they compare? Allstate Corp trades at $260.88 (market cap $66.31B), while Inovio Pharmaceuticals Inc trades at $0.73 (market cap $78.55M). The key difference: Allstate Corp is far larger — about 844.2× Inovio Pharmaceuticals Inc's market cap, and Allstate Corp pays a 1.65% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

ALLINO
Market Cap
$66.31B$78.55M
Sector
FinancialsHealth
52-Week High
$275.11$2.87
52-Week Low
$190.00$0.66
Enterprise Value
$74.96B$49.56M
Dividend Yield
1.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Allstate Corp

Allstate (ALL) trades at $269.67, up 1.0% today, near its 52-week high. The stock shows bullish technical signals with strong support at $267. Fundamentally, the company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, with revenue growth and improved underwriting profitability. The P/E ratio of 5.25 indicates attractive valuation relative to earnings. Recent news highlights strong operational performance but questions sustainability.

Outlook is positive with earnings beats and dividend payments, but risks include potential normalization of underwriting margins and competitive pressures. Analyst consensus is mixed with a $266.47 price target, suggesting limited upside from current levels. Investment appeal lies in valuation and profitability, though sustainability concerns warrant caution.

Inovio Pharmaceuticals Inc

INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.

Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Allstate Corp

On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.

Read more on ALL

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO